Antibodies
DEEP technology is being developed for antibody production against targets that include multispan membrane proteins, heat shock proteins and others; and for research and diagnostic and therapeutic uses.
DEEP™ takes advantage of Peptimmune’s know-how in the solid-phase manufacturing of complex peptide mixtures. The technology combines the epitope specificity of a fixed-sequence peptide with the randomness of a broadly immune-interactive copolymer. DEEP is derived from iterative screening, positional scanning peptide libraries, altered peptide ligands, dendrimers/MAPs, and random-sequence copolymers. The DEEP technology can be used to create cost-effective antibody ligands that generate specific antibody diversity.
Current Antibody Production
- Inefficient
- Current peptide ligands produce limited antibody paratopes
- Yields low numbers of functional clones
- Costly
DEEP technology is being developed for antibody production against targets that include multispan membrane proteins, heat shock proteins and others; and for research and diagnostic and therapeutic uses.
